Companies Kezar Life Sciences
Kezar Life Sciences (KZR): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Kezar Life Sciences’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,602,155FY2023
- $927,300FY2024
CEO total pay was $927,300 in fiscal 2024, down from $2,602,155 in fiscal 2023.
FY2024: salary $600,000 · bonus $0 · stock awards $0 · option awards $0
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Kirk | $600,000 | $0 | $0 | $0 | $313,500 | $0 | $13,800 | $927,300 |
| Chief Executive Officer | ||||||||
| Marc Belsky | 462,000 | 0 | 0 | 261,835 | 177,408 | 0 | 13,800 | 915,043 |
| Chief Financial Officer | ||||||||
| Mark Schiller | 451,000 | 0 | 0 | 230,393 | 173,185 | 0 | 13,800 | 868,378 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Christopher Kirk | $927,300 | $2,602,155 | — | ↓ −1,674,855 |
| Marc Belsky | 915,043 | 2,006,319 | — | ↓ −1,091,276 |
| Mark Schiller | 868,378 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Compensation of our named executive officers is designed to enable the Company to attract and retain talented and experienced executives to lead us successfully in a competitive environment. We believe that our compensation policies and decisions are consistent with current market practices.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mark Schiller | Option | 230 | 22.8 | — |
| Marc Belsky | Option | 458 | 22.8 | — |
| Christopher Kirk | Option | 542 | 22.8 | — |
| Mark Schiller | PSU | 1,500 | — | 10,080 |
| Mark Schiller | Option | 3,520 | 22.8 | — |
| Marc Belsky | Option | 3,791 | 22.8 | — |
| Christopher Kirk | Option | 4,604 | 22.8 | — |
| Mark Schiller | Option | 8,593 | 22.8 | — |
| Christopher Kirk | Option | 9,896 | 22.8 | — |
| Marc Belsky | Option | 10,156 | 22.8 | — |
| Marc Belsky | Option | 12,000 | 6.3 | — |
| Mark Schiller | Option | 12,000 | 6.3 | — |
| Mark Schiller | Option | 19,271 | 9.3 | — |
| Marc Belsky | Option | 22,739 | 9.3 | — |
| Christopher Kirk | Option | 63,803 | 8.4 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Graham CooperIndependent · Audit Committee (Chair) · Compensation Committee | $90,000 | — | $24,375 | — | — | $114,375 |
| Elizabeth GarnerIndependent · Audit Committee | 57,500 | — | 24,375 | — | — | 81,875 |
| Franklin BergerIndependent · Audit Committee · Nominating and Corporate Governance Committee (Chair) | 55,500 | — | 24,375 | — | — | 79,875 |
| Micki KlearmanIndependent · Nominating and Corporate Governance Committee | 54,000 | — | 24,375 | — | — | 78,375 |
| Courtney WallaceIndependent · Compensation Committee · Nominating and Corporate Governance Committee | 49,000 | — | 24,375 | — | — | 73,375 |
| John FowlerIndependent | 57,037 | — | 0 | — | — | 57,037 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $363,037 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $363,037 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Kezar Life Sciences as a peer
Companies that benchmark against KZR
4 companies name KZR as a compensation peer
The list of companies that name KZR as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Kezar Life Sciences | 2024 | Christopher Kirk | $600,000 | $0 | $0 | $313,500 | $927,300 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (12 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Christopher Kirk. DEF 14A, filed 2025-04-25. Section “Executive Compensation” · page 20. As printed: 927,300. View filing ↗
- Section 01, Marc Belsky. DEF 14A, filed 2025-04-25. Section “Executive Compensation”. As printed: 915,043. View filing ↗
- Section 01, Mark Schiller. DEF 14A, filed 2025-04-25. Section “Executive Compensation”. As printed: 868,378. View filing ↗
- Section 08, Graham Cooper. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 114,375. View filing ↗
- Section 08, Elizabeth Garner. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 81,875. View filing ↗
- Section 08, Franklin Berger. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 79,875. View filing ↗
- Section 08, Micki Klearman. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 78,375. View filing ↗
- Section 08, Courtney Wallace. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 73,375. View filing ↗
- Section 08, John Fowler. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 57,037. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 363,037 + equity 0 + all other 0 = 363,037, summed across the director compensation table rows.
- Kezar Life Sciences (subject), Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Kezar Life Sciences's own proxy. As printed: 927,300. View filing ↗